Multi-platform molecular profiling of 1,180 patients increases median overall survival and influences treatment decision in 53% of cases


David Spetzler, Nick Xiao, Ken Burnett, Katie Burch, Brian Abbott, Kenneth Russell, Andreas Voss, Zoran Gatalica, Sandeep Reddy, Robert Leonard, David Khayat, John Marshall


A prospective, observational study was initiated in 2009 with IRB approval to track outcomes and determine the clinical utility of multi-platform molecular profiling (MMP) across a variety of solid tumors. A secondary objective was to assess the impact of MMP on physicians’ treatment decisions.

Download Publication